^
    19h
    ZGR in SBLPN: Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial (clinicaltrials.gov)
    P2, N=47, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    1d
    BGB-11417-108: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    1d
    BGB-3111-215t: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Trial completion date: Oct 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    2d
    Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies (clinicaltrials.gov)
    P=N/A, N=15000, Not yet recruiting, University Hospital, Caen
    New trial
    |
    Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    8d
    A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, BeOne Medicines
    New P3 trial
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • sonrotoclax (BGB-11417)
    10d
    A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies (clinicaltrials.gov)
    P2, N=108, Not yet recruiting, Curis, Inc.
    New P2 trial
    |
    Brukinsa (zanubrutinib) • emavusertib (CA-4948)
    11d
    Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma (clinicaltrials.gov)
    P4, N=40, Recruiting, The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Rituxan (rituximab) • Jakafi (ruxolitinib) • Brukinsa (zanubrutinib)
    11d
    GUIDANCE05: Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL (clinicaltrials.gov)
    P2, N=152, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • decitabine • prednisone • Polivy (polatuzumab vedotin-piiq)
    13d
    Zanubrutinib and Venetoclax in CLL (ZANU-VEN) (clinicaltrials.gov)
    P2, N=45, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib)
    14d
    Management of autoimmune hemolytic anemia. (PubMed, Hematology Am Soc Hematol Educ Program)
    Rituximab is now the preferred second-line option for relapsed/refractory patients, comparing favorably with the traditional splenectomy. The latter is increasingly reserved for later lines together with classic immunosuppressants. Several novel treatments are in development for refractory wAIHA, encompassing drugs targeting B-cells (parsaclisib, ibrutinib, rilzabrutinib, zanubrutinib, obexelimab, ianalumab, povetacicept), plasma cells (bortezomib, daratumumab), spleen tyrosine kinase (fostamatinib, sovleplenib), and the neonatal Fc receptor (nipocalimab).
    Review • Journal
    |
    SYK (Spleen tyrosine kinase)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib • Brukinsa (zanubrutinib) • Darzalex (daratumumab) • parsaclisib (INCB50465) • Tavalisse (fostamatinib) • ianalumab (VAY736) • sovleplenib (HMPL-523)
    14d
    Solitary Hepatic Plasmacytoma With IgM Monoclonal Gammopathy: A Case Report. (PubMed, Case Rep Hematol)
    The patient demonstrated excellent clinical and radiographic response to zanubrutinib therapy by way of improvement in IgM and the size of the liver mass...To our knowledge, this represents one of the few documented cases of IgM-secreting solitary hepatic plasmacytoma. This case highlights diagnostic challenges, the importance of immunophenotypic profiling, and the need for individualized management strategies in this rare entity.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PAX5 (Paired Box 5) • SDC1 (Syndecan 1)
    |
    Brukinsa (zanubrutinib)
    16d
    Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    lenalidomide • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)